

FSD Pharma

17:25 12 Jun 2019

FSD Pharma bolsters its board of directors with a pair of fresh faces

FSD Pharma Inc (CSE:HUGE) (OTCMKTS:FSDDF) is beefing up its board of directors, the company announced Wednesday.

James Datin, CEO of the bioanalytics lab BioAgilytix, and Robert Ciaruffoli, the co-founder and vice chairman of the 100-member angel investor network Broad Street Angels, are joining the board.

The company's stock was flat at C\$0.20 in Toronto and climbed 0.8% to US\$0.15 on OTC Markets.

Under Datin's leadership, BioAgilytix was named to the Inc. 5000 list of Fastest Growing Private Companies in America six times and selected as the Contract Research Organization of the year in North Carolina. He oversaw the company's expansion into Europe with the acquisition of Hamburg-based lab IPM Biotech.

READ: FSD Pharma adds two leading cannabis researchers to Scientific Advisory Board

Ciaruffoli, a CPA, helps lead the largest angel investor network in the Philadelphia region. Prior to that, he served as CEO and Chairman of the accounting firm Parente Beard/Baker Tilly. He transformed the firm from a Philadelphia company to a regional one. He oversaw the merger between the Parente Beard and Baker Tilly Virchow Krause firms, which created the 12th largest such firm in the US.

"It is an honor to welcome Jim Datin and Bob Ciaruffoli to the FSD Pharma Board of Directors," CEO and Co-Chairman Raza Bokhari said. "The experience and expertise they both bring as C-level entrepreneurial executives, leaders and board members of impressive organizations will add tremendous value to FSD. Both gentlemen have been instrumental in achieving outstanding growth for their respective companies, in raising capital to fuel growth opportunities and in driving sustainable shareholder value."

FSD Pharma is a producer of pharmaceutical grade cannabis with facilities in Toronto and Ontario. It operates a research and development platform focused on cannabinoid-based treatments for central nervous system disorders such as fibromyalgia and Irritable Bowel Syndrome.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter [@andrew_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private

Price: 5.8

Market Cap: \$45.33 m

1 Year Share Price Graph



December 2018 June 2019 December 2019

Share Information

Code: HUGE

Listing: CSE

52 week High Low
89.445 4.4

Sector: Cannabis

Website: fsdpharma.com

Company Synopsis:

FSD Pharma is a publicly traded company on the Canadian Securities Exchange under the symbol HUGE. The Company, through its wholly-owned subsidiary FV Pharma Inc. , holds an ACMPR license to cultivate cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR).

action@proactiveinvestors.com

investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).